Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H2, 2018

GlobalData
620 Pages - GLDATA64821
$2,500.00

Summary

GlobalData's clinical trial report, “Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H2, 2018" provides an overview of Transitional Cell Cancer (Urothelial Cell Cancer) clinical trials scenario. This report provides top line data relating to the clinical trials on Transitional Cell Cancer (Urothelial Cell Cancer). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Companies Mentioned
F. Hoffmann-La Roche Ltd
Merck & Co Inc
Bristol-Myers Squibb Co
AstraZeneca Plc
Pfizer Inc
Eli Lilly and Co
Incyte Corp
GlaxoSmithKline Plc
Bayer AG
Amgen Inc

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 18
Clinical Trials in G7 Countries by Trial Status 19
Clinical Trials by E7 Countries: Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials 21
Clinical Trials by Phase in E7 Countries 23
Clinical Trials in E7 Countries by Trial Status 24
Clinical Trials by Phase 26
In Progress Trials by Phase 27
Clinical Trials by Trial Status 28
Clinical Trials by End Point Status 30
Subjects Recruited Over a Period of Time 31
Clinical Trials by Sponsor Type 32
Prominent Sponsors 33
Top Companies Participating in Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials 35
Prominent Drugs 37
Latest Clinical Trials News on Transitional Cell Cancer (Urothelial Cell Cancer) 39
Jul 09, 2018: Seattle Genetics completes enrolment in EV-201 trial 39
Clinical Trial Profile Snapshots 40
Appendix 618
Abbreviations 618
Definitions 618
Research Methodology 619
Secondary Research 619
About GlobalData 619
Contact Us 620
Disclaimer 620
Source 620

List of Tables
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Region, 2018* 7
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 14
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 15
Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, G7 Countries (%), 2018* 17
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 20
Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, E7 Countries (%), 2018* 22
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 23
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 25
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Phase, 2018* 26
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 27
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 29
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 30
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 31
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 32
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 34
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 36
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 38

List of Figures
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 14
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 15
Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, G7 Countries (%), 2018* 16
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 19
Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, E7 Countries (%), 2018* 21
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 23
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 24
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 26
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 27
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 28
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 30
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 31
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 32
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 33
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 35
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 37
GlobalData Methodology 619

$2,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports